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Abstract: 
Introduction: Dilation and evacuation is the most common method of second-trimester 
pregnancy termination procedures. Studies have shown the mortality rate of these 
procedures to be 4.9/100,000. Patient safety during an abortion is a vital component of 
women's health. Second-trimester abortions have been shown to have an increased risk 
of adverse events over first-trimester procedures. This implies there may be an increased 
risk of adverse events with increasing gestational age within the second-trimester. This 
study investigates the influence of gestational age on the risk of serious adverse outcome 
of second-trimester surgical abortions. 
Methods: Retrospective analysis of active surveillance of adverse event data from 2,218 
women presenting for second-trimester termination procedures at 18 Planned Parenthood 
Federation of America sites was performed to analyze the risk for serious adverse event 
among patients with gestational ages 12-15 6/7 weeks compared to 16-23 6/7 weeks. 
Patient care was not changed in any manner during the data collection. Age of patient, 
parity, history of C-section, and BMI and treatment regimen were included in the 
analysis. 
Results: Preliminary results show 10 serious adverse events for the 2, 218 procedures: 6 
hemorrhages greater than 500 cc, 1 cervical laceration requiring repair, 1 incomplete 
abortion, 1 infection, and 1 case of shaking/nausea/chills requiring admission for 
observation. Risk Ratios, adjusted for confounding of a second characteristic, are 
presented. 
Conclusions: Dilation and evacuation is a safe method of second-trimester pregnancy 
termination, but we should continue to analyze risk factors of adverse events in order to 
increase safety ofthe procedure. 
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Introduction: 
Dilation and evacuation is one of the most common forms of therapeutic abortion. 
Dilation and evacuation, like all medical procedures does incur some risk to the patient. 
Many researchers have investigated many different aspects of therapeutic abortion safety. 
There has been little research on the effect of misoprostol on ripening of the cervix for 
second trimester procedures. Theoretically misoprostol softens the cervix and allows for 
dilatation safer than without. In the past laminaria tents have been used to dilate the 
cervix adequately. 
Despite these improvements in dilatation technique, there is still a need to discover the 
risk factors of serious adverse events. Patients who have serious adverse events are rare, 
but their characteristics may help researchers discover which type of patients are 
increased risk of adverse event following a second trimester procedure. 
Purpose: 
The purpose of this study is to evaluate the relative risk of increasing gestational age in 
second-trimester abortions on the occurrence of serious adverse events. 
Hypothesis: The risk of adverse events increases with gestational age. We will compare 
the rate of serious adverse events between the lower 12-15 6/7 weeks and gestational ages 
16-23 6/7 weeks. These data will provide an estimate of the risk of pregnancy 
termination at higher gestational ages, which can be used to educate patients, as well as 
add to our current knowledge of pregnancy termination safety. These data will also lead 
to further studies that have the potential to further evaluate the gestational ages that may 
be associated with an increase in adverse events. 
Background & Significance 
Studies have shown that second-trimester dilation and evacuation abortions are safe 
procedures with mortality risks of 4.91100,000 procedures.1 Although this is a very safe 
medical procedure, researchers and clinicians still are searching for methods to make this 
procedure safer. Second-trimester abortions have been reported to be associated with an 
increase risk of adverse events compared to first trimester procedures. 2 Since the 
legalization oftherapeutic abortions, the number of abortions performed in the United 
States has increased dramatically. In addition, the ratio of first-trimester abortions to 
second-trimester abortions has increased due to increased access to services. This trend 
is favorable considering the increased risk of complications associated with second-
trimester procedures. 3 Second-trimester pregnancy terminations have a significantly 
higher rate of serious complications than first trimester abortions. A retrospective review 
found that the uterine perforation rate in first-trimester procedures was 0.05% while 
second-trimester procedures had a uterine perforation rate of 0.31 %. 4 Despite this 
increase risk in complication rate, there continues to be a need for second-trimester 
termination procedures. Since there is a significant increase in risk with gestation age 
from first-trimester procedures to second-trimester procedures, it follows that late 
second-trimester abortions may have an increased risk of adverse events over early 
second-trimester abortions. This question has yet to be investigated thoroughly. 
Although second-trimester abortions comprise only 12% of the reported abortion cases, 
this still comprises over 100,000 procedures per year. In addition, 5.8% of abortions 
accounting for approximately 50,000 procedures were performed after 16 weeks of 
gestational age. 5 Even with the extremely low complication rates, the large volume of 
second-trimester pregnancy terminations makes the morbidity of these procedures a 
significant issue in women's health. 
Adverse events: 
This study will investigate the increase risk of serious adverse events as the 
gestational age increases in second-trimester abortions. The serious adverse events 
include hemorrhage and cervical laceration which have been shown to be significant risk 
factors for hysterectomy and death after abortion. 6 Cervical laceration can be life 
threatening due to hemorrhage and also may require hysterectomy. 7 Excessive 
hemorrhage is also a concerning adverse event and can lead to diagnostic surgeries, 
hysterectomy and other high morbidity outcomes. 8 With the data suggesting an increased 
incidence ofthese risk factors for adverse outcomes for second-trimester abortions over 
first trimester abortions, data are needed to evaluate the increase risk as gestational age 
increases in the second-trimester. 
Mortality 
Mortality is a rare complication of abortion accounting for 0.6 deaths per 100,000 
procedures.9 Although this is extremely rare and well below the maternal mortality rate 
of carrying the pregnancy to term, this is still a very significant adverse event because of 
the severity. Reducing the risk factors, such as hemorrhage and uterine perforation 
should reduce the mortality rate as well. Since the mortality rate is so low, this is a 
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challenging outcome for research purposes. This is why we chose hemorrhage, uterine 
perforation, and cervical laceration markers for increased risk of mortality. 
Hemorrhage 
The rate of significant hemorrhage is difficult to assess because of lack of a 
standard definition of severe/significant hemorrhage. Many authors have used 
hemorrhage requiring transfusion as a standard, but this is still ambiguous because of the 
variation in transfusion practices per provider, over time, and at different institutions. In 
addition, hematocrit For the purpose of this study, we will define excessive hemorrhage 
as greater than 500 ml as estimated by the operator. 
Cervical laceration/Uterine Perforation 
Although rare, uterine perforation is associated with hemorrhage, infection, and 
injury to the intestines and other abdominal organs. In addition, uterine perforation 
increased the risk of death by 100 fold, and uterine perforations also are identified as the 
cause of two-thirds of hysterectomies from abortions. 10 Reported rates of uterine 
perforation may be grossly underestimated. Adequate cervical dilation is key to 
preventing such injuries. 11 
Long-term consequences of uterine perforation may include uterine rupture in 
subsequent pregnancies. In a retrospective study of 13,907 women, Pridmore and 
Chambers analyzed the risk factors of uterine rupture in surgical pregnancy termination. 
The study found an increase risk in perforation rates with an increase in gestational ages 
in the second-trimester 0.2% for 13-16 weeks and 1.7% for 17-20 weeks. History of 
previous Ceasarean section (C-section) also increased the risk of uterine perforation from 
0.26% to 5%.12 Cervical laceration usually occurs when the tenaculum falls off of the 
cervix, usually during dilation. Proper pre-procedural dilation is the best method for 
reducing cervicallacerations.13 
Future pregnancy loss: It has been postulated that second-trimester abortions 
may lead to cervical incompetence and an increase in spontaneous abortions and 
premature births in subsequent pregnancies.14 In a retrospective review, Kalish eta! 
reported no increase in pregnancy loss among 600 patients who underwent second-
trimester surgical abortions. Of these 600 women, 96 subsequent pregnancies were 
noted. These cases were compared to controls at the hospital and were not found to have 
an increase risk of fetal loss, cervical incompetence, or pre-term delivery. The authors 
did note a correlation between earlier gestational age at time of pregnancy termination 
and subsequent pre-term delivery. The authors postulated this was due to less pre-
procedure dilation, and subsequent intra-procedural cervical trauma. 15 Frank et. a! also 
found no significant increase in subsequent pregnancy loss after second-trimester 
abortion, with a relative risk of 1.01 (95% CI 0.81-1.27) 
Procedure Methods: 
Induction oflabor: 
Evidence of induction of labor for termination of pregnancy traces back to ancient 
Egyptian writings, Greek philosophy, Biblical references in the New Testament and early 
Islamic law of 1000-1400 AD. Early laws allowed for abortions, until the onset of 
quickening. Many of the early concoctions utilized for induction were later proven to be 
without merit, but the Acacia plant used by ancient Egyptians is currently used as 
contraceptive in some developing countries today. In twentieth-century America, 
induction methods of abortion were developed and widely utilized, especially for second-
trimester terminations. The following methods were developed. 16 
Hypertonic Saline Instillation: 
Hypertonic Saline Instillation was used in the late 1960's and early 1970's as the method 
of choice for second-trimester abortions. The procedure involves the removal of 50-250 
ml of amniotic fluid, followed by the instillation of 50-250 m1 of20% hypertonic saline 
by either a trans-abdominal, or trans-cervical approach. This method was fairly effective 
with 97% of women delivering within 72 hours. The procedure had a high morbidity rate 
with patient discomfort, hypernatremia, coagulopathy, hemorrhage, infection, uterine 
rupture, and cervicallaceration.17 
Prostaglandin infusion: 
Later prostaglandin infusion was introduced with the following advantages over 
hypertonic saline infusion: Low dose infusion with minimal complications if 
inadvertently injected intravascularly, increased ease of procedure during the early-
second trimester, lower coagulopathy rate, and lower cervical laceration rate. The 
disadvantage of this procedure is the requirement of repeated injections and the presence 
of an indwelling catheter that increases the risk of infection.18 
Hyperosmolar urea infusion: 
Hyperosmolar urea infusion was also utilized as an alternative induction oflabor method. 
The advantages of this technique included predictable injection to time of abortion 
intervals, ease of technique, limited coagulation and hematological changes, and a low 
frequency oflife-threatening complications. However, the technique usually required 
adjunctive prostaglandin injection, and still carried a 30-40% rate of incomplete abortion, 
requiring curettage. 19 
Surgical methods: 
Hysterotomy involved a surgical opening of the uterus and manual emptying, followed 
by repair of the uterus. This method involved excessive morbidity and mortality, and 
excessive cost, and was abandoned early. 
Dilation and evacuation: 
Dilation and evacuation was developed because of the drawbacks of the induction of 
labor methods. Dilation and evacuation involves mechanical dilation of the cervix, 
followed by traction of the fetal parts. Dilation and evacuation allows for a quick, 
definitive abortion, without the excessive risk of hysterotomy, or the unpredictable, ! 
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prolonged course of induction techniques. The use oflaminaria for dilation increased the ~ 
ease of the procedure and decreased the side effects as well.20 
Grimes and Schulz analyzed the relative safety of different second-trimester procedure 
methods, hysterotomy and hysterectomy, dilation and evacuation, and induction methods. 
Dilation and evacuation procedures had a mortality rate of 4.9 per 100,000 procedures, 
9.6 per 100,000 for induction methods, and over 60 for hysterotomy and hysterectomy. 
Dilation and evacuation procedures also were associated with lower stress levels to the 
patient. Local anesthesia and adequate pre-procedural cervical dilation were also found 
to be associated with less risk. 21 
Autry et al found that surgical dilation and evacuation was associated with less risk of 
complications than medical induction for second-trimester abortion. Included in the 
complications was the need for dilation and evacuation of retained products of 
conception, which occurred, in 21% of medical abortions. This study also showed that 
patients with a prior uterine scar and those with less laminaria were at increased risk of 
complications (OR 2.4 95% CI 1.0-5.7 and OR 0.9 95% CI 0.8-1.0). Complications were 
also more likely to be associated with blood loss greater than 500 cc (OR 6.4; 95% CI 
) 22 1.9-21.8 . 
Innovations in D&E: 
For dilation and evacuation procedures pre-procedural cervical dilation has been shown 
to decrease morbidity and mortality. Osmotic dilators, such as laminaria, have been used 
as the standard method of pre-procedural dilation?3 Recently misoprostol, a synthetic 
prostaglandin El analogue, has been used in adjunct to and in replacement oflaminaria 
for pre-procedural cervical dilation. Misoprostol has been shown to provide equal or 
greater cervical dilation to laminaria. In addition, misoprostol administration is 
associated with less pain than laminaria.24 Originally, misoprostol was administered 
vaginally for cervical priming in abortion procedures. Other routes of administration 
have been postulated to have advantages over vaginal administration. Carbonell et. a! 
investigated vaginal versus oral administration. The authors found that oral 
administration of misoprostol was associated with less discomfort than vaginal 
administration, but vaginal administration generated significantly higher cervical dilation 
8.1cm vs. 8.5 em (p=0.0001).25 
The administration of fetocidal agents prior to procedure has also been shown to ease 
dilation and evacuation procedures. Transabdominal injection of digoxin into the 
amniotic fluid or fetus is safe and effective in causing fetal demise. Early fetal demise 
allows for softening of the cortical bone of the fetus allowing easier passage through the 
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cervix. 
Methods: Between June 2002 and April2003, Planned Parenthood Federation of 
America participated in active surveillance of adverse events for patients receiving buccal 
misoprostol as a primary cervical ripening agent, or as an adjunct to laminaria for 
cervical ripening in second-trimester surgical abortions. Patient care was not changed in 
any way during the study. Data for 2,218 women at 18 affiliate sites were compiled into 
a computerized data set for analysis. Hemorrhage greater than 500cc (as determined by 
the surgeon), cervical laceration, uterine perforation, fever, and other adverse events were 
recorded. In addition, demographic data, such as age, parity, history of c-section, and 
gestational age at time of procedure were also recorded. Procedures were performed 
following usual practice among the affiliates using the PPF A Standards and Guidelines 
along with some clinician preference. Some patients received supplementallaminaria the 
day before and, often, the day of the procedure. A separate Adverse Event Report was 
completed for each noted possible adverse event. The adverse events were categorized as 
serious or non-serious by independent review by four physicians. In cases of conflict, the 
cases were reviewed by 3 physicians until a consensus was reached. The patients were 
then stratified into two groups based on gestational age, 12-15 6/7 weeks and 16-23 6/7 
weeks. These two groups were analyzed for the occurrence of serious adverse events. 
Chi-square tests and Fisher's exact tests were performed to test the primary hypothesis. 
Relative risk and trend analyses will examine the strength of association. A probability 
of 0.05 will be used as a cutoff for statistical significance. Since this is an exploratory 
study, a probability level of 0.10 will be suggestive of further study. 
Results: 
Data for 2,154 women were collected. Table -One displays the demographic data of the 
data set. Subjects are divided by gestational age, age, parity, history of c-section, and 
type of anesthesia. The number of subjects in gestational age ranges, 12-15 6/7, and 16-
23 weeks is shown. Age is depicted as agel4-21 years and age greater than 21 years. 
Body Mass Index is divided into <24.9 and greater than or equal to 25. The number and 
percent of nulliparous and mulitparous women is also displayed as well as women with a 
history of a c-section. 
Figure 1 depicts the distribution of gestational age in the sample, the number of subjects 
in gestational age ranges, 12-13 6/7, 14-15 6/7, 16-17 6/7, 18-19 6/7, and >20 weeks is 
shown. 
Table-2 displays the adverse events found in our study. There are a total of 10 adverse 
events that were serious adverse events. Six patients experienced hemorrhage greater 
than 500cc. One patient experienced a cervical laceration, one an incomplete abortion, 
one sepsis, and one shaking/nausea/chills. Hemorrhage greater than 500cc was the most 
common serious adverse event with a rate of2.71 per 1,000 patients. 
Table 3 illustrates the number of cases, percent of cases, and total number of procedures 
for age, body-mass-index (BMI), parity, previous C-section, and gestational age. Women 
ages 22 and greater were 8.38 times more likely to have a serious adverse event than 
;:---
those ages 21 or less (CI 1.06- 66.23). Multiparous women were more likely to 
experience an adverse event than nulliparous women, with a p<O.Ol97. Women with a 
history of c-section are 3.99 times more likely to experience a serious adverse event than 
those without a history, but this is no statistically significant, with a p<0.12. Patients 
with lower gestation ages, 12-15 had a higher serious adverse event rate, however this 
association was not statistically significant. 
Table 4 illustrates the occurrence of adverse events among gestational age groups, and 
any association with selected patient characteristics (patient age, BMI, parity and history 
of C-section) BMI, parity and history of C-section within each gestational age. In women 
ages 22 and greater, the serious adverse event rate is higher for gestation ages 12-15 6/7(p 
< 0.0393). In addition, patients with a BMI greater than or equal to 25 and gestational age 
16-23 weeks were at greater risk ofSAE (p <0 .0503). 
Conclusions: 
Single variable analyses indicate that older patients and multiparous 
patients are a greater risk for serious adverse event. Gestational age, alone, does not 
appear to be a risk factor for serious adverse events, however when patients are divided 
into two gestational age groups, there is some evidence to indicate that two groups 
of women are at greater risk of an serious adverse event: older patients with gestational 
age under 16 are at greater risk of a serious adverse event ; and patients with BMI 25 and 
higher and with gestational age 16 or higher are at greater risk of an serious adverse 
event. In this small sample size, gestational age by itself did not show a statistically 
significant result, however when combined with age of the patient, there was a 
statistically significant result. This implies that there is some association with gestational 
' age that warrants future investigation. 
Studies with a larger sample size or more frequent serious adverse events, or randomized 
control trials are needed to confirm these results and test other suggestive hypotheses, 
e.g., association between history of C-section and serious adverse events. 
Contrary to our hypothesis, increasing gestational age did not show an increased risk of 
serious adverse events. This is consistent with Kalish et. a! that found a correlation 
between preterm delivery and lower gestational ages of second-trimester abortions at. 
Kalish postulated that this could be due to a lack of adequate cervical preparation and 
pre-procedural dilation in the lower gestational ages of the second-trimester. 27 This 
phenomenon may also be caused by biological ripening of the cervix as gestational age 
increases in preparation for the birthing process. History of C-section was associated 
with an increase in serious adverse event rates, but this association was not statistically 
significant. To the contrary, Pridmore and Chambers's findings of increased risk in 
women with a history of C-section were statistically significant?8 These data are 
important for patients with a history of C-section that are presenting for pregnancy 
termination. Studies are needed to determine what safety measures can be performed to 
decrease this risk, and what measures should be taken in post-procedure management to 
prevent these events from leading to adverse outcomes, such as hysterectomy and death. 
Haste in performing the procedure, inadequate pre-procedural cervical dilation with 
larninaria and or misoprostol, underestimation of gestational age, and biological 
differences in the cervix all may contribute to an increase in adverse events. 
Age greater than 22 years proved to be a significant risk factor for serious adverse events. 
This is important information for patients who present for second-trimester terminations 
due to congenital anomalies. These patients are more likely to be older, and this 
increased risk must be discussed and considered with their management. Further studies 
are necessary to better quantify this risk and investigate the possible causes. 
Parity was shown to have a statistically significant association with serious adverse 
events, with multiparous women experiencing higher rates of serious adverse events. 
This was an unanticipated finding. 
Future studies: As the number of second-trimester abortions remains constant, and the 
incidence of adverse outcomes remains much higher than first-trimester procedures, there 
is a need for a greater understanding of the risk factors involved in second-trimester 
procedures. This study demonstrates the need for analysis of age of patient, history of C-
section, as well as further analysis of the effect of gestational age within the second-
trimester. Future studies will help clarify the questions raised by the results of this and 
other studies. 
In order to investigate this further, future studies should include pre-procedural 
dilation as well as the amount of mechanical dilation, if any, performed during the 
procedure. This would provide more information on the trauma, if any, to the cervix 
produced by mechanical dilation, versus osmotic dilators (laminaria) and cervical 
ripening agents (misoprostol) Studies of cervical length, firmness and dilation may assist 
in evaluating the biological effect of cervical ripening as gestational age increases. 
There were some limitations to our study. This was a retrospective review of a data set 
that was not designed to compare gestational age and its association with adverse events. 
There was also a lack of standardization of procedure, including anesthesia. The sample 
size was somewhat small considering the event rate of our adverse events, and may have 
affected the results. 
There is a need for a greater understanding of the risk factors involved in second-
trimester pregnancy termination procedures in order to continue to decrease the adverse 
event rate. The exact mechanism of cervical injury and the precautions that should be 
taken to minimize these injuries must be examined further. Further investigation of 
misoprostol and its effect on limiting damage of the cervix during dilation and evacuation 
can lead to further decreases in adverse events from dilation and evacuation procedures. 
Although the adverse event rate of second-trimester dilation and evacuation procedures 
has decreased significantly over the past few decades, more research is needed to provide 
the safest possible procedures to women presenting for second-trimester pregnancy 
terminations. 
Table-1 Patient Demographics for 2,154 Patients 
Total 
Patient Demographics N % 
Gestational Age 
12-15 930 43.2 
16-23 1224 56.8 
Age 
14-21 966 48.0 
>21 1046 52.0 
Body Mass Index ~ 
<24.9 1037 54.0 
>=25 883 46.0 
F 
Parity 
Iii 
r Nulliparous 719 33.8 
Mulitparous 1407 66.2 
History of a C-Section 
Yes 123 6.0 
No 1939 94.0 
~ 
*Frequencies do not sum to 
2,154 due to missing data. 
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Figure-1 Distribution of Gestational Age 
12-13 5/7 14-15 6/7 16-17 6/7 18-19 6/7 20-21 6/7 22-24 0/7 
Gestational age 
Table-2 Description of Serious Adverse Events. 
Number Rate/1,000 Patients Event 
6 
1 
1 
1 
1 
2.71 
0.45 
0.45 
0.45 
0.45 
Hemorrhage>500cc 
Cervical Lacerations 
Incomplete Abortion 
Sepsis 
Shaking/Nausea/Chills 
Table 3. Patient Demographics Associated With Serious Adverse Event 
Total Cases Non-Cases 
Patient Demographics N 
Age 
14-21 966 
>=22 1046 
Body Mass Index 
<24.9 1037 
>=25 883 
Parity 
Nulliparous 719 
Mu1itparous 1407 
History of a C-Section 
Yes 123 
No 1939 
Gestational Age 
12-15 930 
16-23 1220 
Women 22 years or older: Odds Ratio 8.38 (1.06- 66.23) 
Mulitparous women: Odds Ratio 10.81 (0.63 -184.77) 
History ofC-Section: Odds Ratio: 3.99 (0.41 -- 27) 
N% N 
1 0.10 965 
9 0.86 1037 
P<0.0221 
3 0.29 1034 
5 0.57 878 
0 0 719 
10 0.72 1397 
P< .0197 
2 1.63 121 
8 0.41 1931 
P< .12 
6 0.65 924 
4 0.33 1220 
~ 
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Table 4. Gestational Age Association With Other Demographic Characteristics 
Gestational Age 
12-15 16-23 
Cases Non- % Cases Non- % 
Cases Cases Cases Cases 
Age 
14-21 0 372 0 1 593 0.17 
>=22 6 481 1.23 3 556 0.54 
P<.0393 
BMI 
<24.9 3 418 0.71 0 616 0 
>=25 1 327 0.30 4 551 0.72 
p < .0503 
Parity 
Nulliparous 0 308 0 0 411 0 
Mulitparous 6 602 0.99 4 795 0.50 
P<.19 P< .31 
History of C-section 
Yes 1 45 2.17 1 76 1.30 
No 5 831 0.60 3 1100 0.27 
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Tables: 
Table-1 demographics 
Total 
Patient characteristics N % 
Gest. Age 
12-15 6/7 929 43.1% 
16-23 6/7 1224 56.9% 
Age 
14-21 992 48.0% 
22-30 780 37.7% 
>30 295 14.3% 
(2067) 
BMI 
<24.9 1073 54.2% 
25-30 527 26.6% 
>30 379 19.2% 
Parity 
Nulliparous 729 33.7% 
Mu1itparous 1432 66.3% 
Prev. C-section 
Yes 123 5.9% 
No 1972 94.1% 
*Frequencies do not sum to 
2,218 due to missing data. 
Table-2 Adverse events. 
Number Rate/1000 Patients Event 
13 
9 
0 
5.85 
3.06 
0 
Cervical Lacerations 
Hemorrhage > 500 cc 
Uterine Perforations 
~ 
~ 
~ 
• ~ F 
' 
Table: 3 
Total Cases Non-Cases 
Patient characteristics N N% N 
Age 
14-21 992 7 0.71 985 
22-30 780 5 0.64 775 
>30 295 9 3.05 286 
(2067) (p<0.0009) 
BMI 
<24.9 1073 8 0.75 1065 
25-30 527 8 1.52 519 
>30 379 1 0.27 375 
Parity 
Nulliparous 729 8 1.10 721 
Mulitparous 1432 14 0.98 1418 
Prev. C-section 
Yes 123 4 3.25 119 f.-i' 
No 1972 18 0.91 1954 ' i p <.014) I Gest. Age 
' 
12-15 6/7 929 13 1.40 916 
16-23 6/7 1224 7 0.57 1217 
(P < .047) 
Table 4: 
Gestational Age 
12-15 6/7 16-23 6/7 
Age Cases Non-cases % Cases Non-cases %Cases 
14-21 2 370 0.53 4 590 0.67 
22-30 4 342 1.16 1 414 0.24 
>30 6 134 4.29 2 142 1.39 
p < .005 
BMI 
<24.9 5 416 1.19 2 614 0.32 
25-30 5 684 2.65 3 323 0.92 
>30 1 138 0.72 0 229 0 
Parity 
Nulliparous 4 304 1.30 3 408 0.73 
Mulitparous 9 598 1.48 4 795 0.50 
Prev. C-section 
Yes 
No 
3 
10 
P<0.004 
43 
815 
6.52 1 
1.20 6 
76 
1097 
1.30 
0.54 
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